



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

02 May 2018
EMA/44715/2018

Agenda for

Workshop on draft reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development

3-4 May 2018

Meeting room 3-A

European Medicines Agency, London, United Kingdom



Objectives

To discuss comments received during the public consultation phase and aspects related to methodological approaches and practical challenges for comparisons at quality level.

To gain better understanding of challenges and opportunities of statistical methods used at quality level in order to facilitate further progress in this field.

Programme details

Thursday, 3 May 2018

Order of presentations subject to change

08:30 **Registration**

09:00 **Welcome and introduction**

Thomas Lang, BSWP, AGES (AT) & **Ina-Christine Rondak**, EMA

75'

10:15 **Coffee break**

10:30 **Session A: Problem statements and challenges**

Chair: **Ina-Christine Rondak**, EMA

One size doesn't fit all: Why it should be three different guidances

Bruno Boulanger, EFSPi, Arlenda

20'

Medicines for Europe's view on the application of statistical methodology for comparability

Martin Schiestl, Medicines for Europe, Sandoz

20'

Statistical tests, Bayesian analysis, or heuristic rules for demonstration of analytical biosimilarity?

Richard Burdick, AAPS, Elion Labs

20'

Challenging issues in biosimilar regulatory submission in the United States

Shein-Chung Chow, FDA (USA)

20'

Discussion introduced by Chair

30'

12:30 **Lunch break**

13:30 **Session B: Case studies with focus on pre-post manufacturing changes**

Chair: **Martijn van der Plas**, BWP, CBG-MEB (NL)

Considerations on biological APIs extracted from material of human and animal origin

René van Herpen, APIC, Aspen Oss BV

20'

Comparability study performed to support a process change for a marketed biological product

Jochen Felix Kepert, EBE, Roche

20'

Pre- and Post-Manufacturing Change for a Biological Product

Christophe Agut, EBE, Sanofi & **Vivien Le Bras**, EBE, Merck

20'

Comparability study to support commercial process change via stability study

Bianca Teodorescu, EBE, UCB

20'

Discussion introduced by Chair

30'

15:30

Coffee break

15:45

Session C: Case studies with focus on Biosimilars

Chair: **Niklas Ekman**, BMWP/BWP, Fimea (FI)

Case studies on statistical tools used for comparability assessment

HyungKi Park, Medicines for Europe, Samsung Bioepis

20'

Practical considerations in the statistical evaluation of biosimilarity – a laboratory perspective

Henriette Kuehne, AAPS, Coherus BioSciences

20'

Analytical similarity

José G. Ramírez, EBE, Amgen

20'

Comparison of Two Groups of Stability Data

Franz Innerbichler, EBE, Novartis

20'

Discussion introduced by Chair

30'

18:00

End of day 1 (for external participants)

18:30

Session D: For regulators only

Learnings from day 1

Workshop organisation committee and session Chairs

45'

19:15

End of day 1 (for all)

08:30 **Welcome and introduction**

08:40 **Session E: Operating characteristics of currently/frequently used similarity criteria**

Chair: **Andreas Brandt**, BSWP, BfArM (DE)

Introduction

Andreas Brandt, BSWP, BfArM (DE) 15'

Operating characteristics of frequently used similarity rules

Florian Klinglmueller, BSWP, AGES (AT) 20'

Performance characteristics of quality range methods and equivalence testing in the comparative assessment of quality attributes

Thomas Stangler, Medicines for Europe, Sandoz 25'

Analytical Similarity Assessment

Shein-Chung Chow, FDA (USA) 20'

Discussion introduced by Chair 30'

10:30 **Coffee break**

10:45 **Session F: New Strategies and alternative methodological approaches**

Chair: **Florian Klinglmueller**, BSWP, AGES (AT)

EMA Case Study: Design of Experiments

Robert Shaw, VE, AstraZeneca 20'

Statistical methodology for biosimilars, comparison of process changes and comparison of dissolution profiles. A perspective from EFSPi

Mike Denham, EFSPi, GlaxoSmithKline 20'

The value of Bayesian statistics for assessing comparability

Timothy Mutsvari, EFSPi, Arlenda 20'

Establishing, Assessing, and Comparing Quality Attributes from a Small Sample of Development Batches through Full-scale Production

Kimberly Vukovinsky, ISPE, Pfizer 20'

Discussion introduced by Chair 30'

12:40 **Closing remarks**

Thomas Lang, BSWP, AGES (AT) 20'

13:00 **End of workshop (for external participants)**

14:00 **Session G: For regulators only**

Learnings from day 2

Workshop organisation committee and session Chairs

120'

16:00 **End of workshop (for all)**

The workshop organisation committee consists of:

Andreas Brandt, BSWP, BfArM (DE)

Niklas Ekman, BMWP/BWP, Fimea (FI)

Thomas Lang, BSWP, AGES (AT)

Jobst Limberg, QWP, BfArM (DE)

Kit Roes, BSWP, CBG-MEB (NL)

Ina-Christine Rondak, EMA

Martijn van der Plas, BWP, CBG-MEB (NL)

Practical information

Venue

The European Medicines Agency can be reached:

- **By Underground**

The nearest stop for Churchill Place is Canary Wharf station on the Jubilee Line. From East exit (NB. This is the closest exit to 30 Churchill Place): exit the station and turn left into Upper Bank Street, turn right at Canada Square and continue straight into Churchill Place.

- **By Docklands Light Railway (DLR)**


The Agency is a short walk from Canary Wharf station on the DLR. Services run from Bank, Tower Gateway, Lewisham, Stratford, King George V and Beckton. Exit into The South Colonnade, turn left towards Canada Square continuing straight into Churchill Place.

- **By car**

There are no parking facilities at 30 Churchill Place and it is recommended that you take public transport. However, four nearby public car parks are operated by Canary Wharf. Rates and further information can be found on the Canary Wharf website:

<http://www.canarywharf.com/aboutus/The-Estate/Travel-/Roads--Parking/>

Map



Arrival at the Agency

On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to access our industry lounge, which you are welcome to utilise during your visit. The industry lounge is located through the sliding doors to the right of the reception desk past the security turnstiles. Your EMA contact point will meet you here.

Physical disability

Let us know if you would like any specific help or information that would make your stay more comfortable. We will be very happy to help.

Registration

We strongly advise you to arrive up to 30 minutes before the start of the workshop, to allow you time for registration and settling down.

Meeting room

Upon arrival each day, please find your allocated seat in the meeting room. Speakers will be able to navigate through their presentation slides from their seats with a pointer, mouse or keyboard.

Presentations

We will not circulate printouts of speakers' presentations. However, you will be able to download them from the Agency's website approximately two weeks after the end of the workshop from this website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2017/09/event_detail_001507.jsp&mid=WC0b01ac058004d5c3

Wi-Fi access & Laptop computers

Wi-Fi is available throughout the EMA. Login details can be found on the back of your EMA access pass.

Media disclaimer

The Agency records or broadcasts a number of its meetings, including some virtual meetings. This is part of the Agency's commitment to the principle of transparency as enshrined in the Treaty on European Union. The Agency herewith informs attendees that this particular meeting will be recorded and broadcast. For more information about processing of personal data by EMA, please visit the website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/general/general_content_000516.jsp&mid

or contact

dataprotection@ema.europa.eu

By attending this meeting you consent to any recording or broadcast.

Conference venue and secretariat

European Medicines Agency

30 Churchill Place, Canary Wharf

London E14 5EU, United Kingdom

Telephone +44 (0)20 3660 7259 | **Facsimile** +44 (0)20 3660 5550

E-mail jolanta.palepsaitiene@ema.europa.eu | **Website** www.ema.europa.eu

For any questions prior to the workshop in relation to the content and participation, please write to RP-stats-QA@ema.europa.eu.